New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 14, 2013
07:25 EDTVSTM, VSTMVerastem management to meet with Leerink
Meeting to be held in Boston on January 17 hosted by Leerink.
News For VSTM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 26, 2015
09:14 EDTVSTMVerastem price target lowered to $23 from $29 at Roth Capital
Subscribe for More Information
January 23, 2015
06:17 EDTVSTMVerastem Secondary increased to 7.25M shares, priced at $6.50
The deal size was increased to 7.25M shares from 4.5M shares. Jefferies and Leerink acted as joint book running managers for the offering.
January 20, 2015
16:04 EDTVSTMVerastem files to sell $40M in common stock
Subscribe for More Information
08:04 EDTVSTMVerastem receives orphan medicinial product designation from EC for VS-5584
Subscribe for More Information
07:05 EDTVSTMVerastem doses first patient in Phase 1 VS-5584 trial
Subscribe for More Information
January 16, 2015
07:03 EDTVSTMVerastem announces publication of scientific data for VS-5584 in cancer research
Verastem announced that a paper, titled “PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells,” has been published in Cancer Research, a peer-reviewed journal of the American Association for Cancer Research. The paper discusses results from preclinical research evaluating VS-5584, a highly potent, selective small molecule inhibitor of mTORC1/2 and Class I PI3K kinases, which preferentially targets cancer stem cells in vitro and in vivo. CSCs represent a subpopulation of cancer cells that have tumor-initiating capability, are particularly resistant to chemotherapy and can mediate tumor recurrence both locally and at metastatic sites. The study results demonstrated that VS-5584 is up to 30-fold more potent in inhibiting the proliferation and survival of CSCs compared to non-CSCs in solid tumor cell populations. VS-5584 preferentially diminished CSC levels in multiple mouse xenograft models of human cancer. Similarly, VS-5584 treatment ex vivo preferentially reduced CSCs in surgically resected breast and ovarian patient tumors. In contrast, chemotherapeutics such as paclitaxel, cisplatin and etoposide effectively targeted bulk tumor cells, but enriched CSCs. Mechanistic investigations revealed that knock down of PI3Kα, PI3Kβ or mTOR alone was insufficient to decrease CSCs, while knock down of PI3Kα, PI3Kβ and mTOR together effectively reduced CSCs mimicking the effect of VS-5584. Consistent with CSC ablation, VS-5584 delayed tumor regrowth following chemotherapy in xenograft models of small cell lung cancer. These data help to elucidate the mechanism of VS-5584 targeting CSCs and provide a strong rationale for the clinical development of VS-5584 in combination with chemotherapeutic agents targeting bulk tumor cells to achieve more durable clinical responses in cancer patients.
05:39 EDTVSTMVerastem risk/reward favorable after pullback, says Mizuho
Subscribe for More Information
January 15, 2015
05:55 EDTVSTMVerastem has meeting hosted by Philadelphia Securities Association
Luncheon Meeting to be held in Philadelphia at 11:30 am on January 15 hosted by Philadelphia Securities Association.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use